What is the Need for Prostatic Biomarkers in Prostate Cancer Management?
(2015) Current Urology Reports — Vol. 16, n° 10, p. Article 70 (2015)
Files
Spahn-2015-Whatistheneedforprostatic.pdf
Restricted Access - Adobe PDF
- 129.33 KB
Details
- Authors
- Abstract
- Discriminating patients with a low risk of progression from those with lethal prostate cancer is one of the main challenges in prostate cancer management. Indeed, such discrimination is essential if we aim to avoid overtreatment in men with indolent disease and to improve survival in those men with lethal disease. We are reporting on the current literature on such prognostic tools that are now available, their clinical role and their limitations in individualizing care. There is an urgent need to incorporate such genomic tools into new platform-based clinical trial structures to further develop and validate prognostic and predictive biomarkers and provide prostate cancer patients with an effective and cost-efficient access to new drugs in the setting of personalized treatment.
- Affiliations
Citations
Spahn, M., Boxler, S., Joniau, S., Moschini, M., Tombal, B., & Karnes, R. J. (2015). What is the Need for Prostatic Biomarkers in Prostate Cancer Management? Current Urology Reports, 16(10), Article 70. https://doi.org/10.1007/s11934-015-0545-3 (Original work published 2015)